Evommune’s stock rallies 70% on Phase IIa eczema data
Evommune’s potential Dupixent competitor has met its primary endpoint in a Phase IIa atopic dermatitis (AD) trial, achieving a 33% …
Post
-
-
How new technologies could transform clinical trial execution
Clinical trials are facing new and evolving challenges as costs increase and approval timelines remain lengthy. Modernisation of processes and …
-
Nektar’s stock rises 51% on Phase II Rezpeg AD maintenance win
Nektar Therapeutics stock has rallied 51% after its lead asset, rezpeg (rezpegaldesleukin), demonstrated potential across monthly and quarterly maintenance dosing …
-
Aardvark gains IRB approval for ARD-101 trial to treat Prader-Willi Syndrome
Aardvark Therapeutics has received Institutional Review Board (IRB) approval in the US for an amended protocol to its Phase III …
-
BioRestorative concludes Phase II BRTX-100 trial enrolment for cLDD
BioRestorative Therapies has concluded patient enrolment in its Phase II study evaluating the efficacy and safety of BRTX-100 for chronic …
-
AstraZeneca to advance in-licensed oral GLP-1RA to pivotal trials
As the oral weight-loss drug market has started to emerge, AstraZeneca has told shareholders that it will advance its candidate …
-
Zenas’ MS drug reduces new brain lesion formation by 95% in Phase II trial
Autoimmune specialist Zenas BioPharma has posted a win for its lead candidate, obexelimab, from a mid-stage study in relapsing multiple …
-
Breye Therapeutics’ oral retinopathy drug shows early improvement in disease activity
Breye Therapeutics’ oral small molecule for non-proliferative diabetic retinopathy (NPDR) has demonstrated safety and early signs of improving disease activity …
-
RWD and RWE are rewriting how we design and run trials
Traditional randomized controlled trials (RCTs) have long been the gold standard for testing new therapies, but they are increasingly strained …
-
Brazilian study shows increase in Covid-19-era substance abuse-related deaths
The societal and economic impacts of the Covid-19 pandemic included a variety of downstream effects on health endpoints worldwide. Among …
-
A New Strategic Blueprint: Designing Smarter Early Phase Trials in Oncology
Cancer drugs form one of the most dynamic segments of pharmaceuticals, powered by rising incidence, ageing populations, deeper cancer biology, …
-
VectorY doses first participant in Phase I/II PIONEER-ALS trial
VectorY Therapeutics has dosed the first participant in its Phase I/II PIONEER-ALS clinical trial, which is investigating VTx-002, a vectorised …
-
By the Numbers: Oncology Trial Activation Timelines and Global Reach
The volume of current activity in the oncology space is enormous. GlobalData’s clinical trial database – a repository of data …
-
Veradermics concludes enrolment in second Phase III VDPHL01 trial
Veradermics has completed enrolment in its second pivotal Phase III clinical trial of VDPHL01 for male pattern hair loss treatment. The …
-
Priovant advances CS drug to Phase III after 100% response in Phase II
Priovant Therapeutics’ cutaneous sarcoidosis (CS) drug has shown response rates of up to 100% on endpoints in a Phase II …
